Liver Safety of the Dual Neurokinin-1/-3 Receptor Antagonist Elinzanetant - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Assessment of Hepatic Safety for the Dual Neurokinin-1/-3 Receptor Antagonist Elinzanetant

  • By

  • James H. Lewis

  • Raúl J. Andrade

  • Dominique Larrey

  • Yves Horsmans

  • Richard A. Anderson

  • Mila Trajanovic

  • Esther Groettrup-Wolfers

  • Lineke Zuurman

  • March 18, 2026

Share

Original Source(s)

Liver Safety of the Dual Neurokinin-1/-3 Receptor Antagonist Elinzanetant

  • by James H. Lewis, Raúl J. Andrade, Dominique Larrey, Yves Horsmans, Richard A. Anderson, Mila Trajanovic, Esther Groettrup-Wolfers, Lineke Zuurman

  • March 18, 2026

Related Content

Correction: Birth weight, ototoxic medication, and surgical history predict individual hearing loss risks: a systematic review and meta-analysis

Correction: Cardiac arrest due to acquired long QT syndrome during gynecologic laparoscopy: a case report

Converging evidence for a two-domain framework of microvascular dysfunction in sepsis